ArticlePLoS neglected tropical diseases2025
Anthropophagic Florida mosquito species are poor vectors of prototype and emerging strains of oropouche virus.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Low Generation Culex quinquefasciatus from Texas and Culex pipiens from New Jersey Are Incompetent Vectors for Oropouche Virus.The American journal of tropical medicine and hygiene · 2026Article
- Screening for Oropouche virus in wild bird samples collected from wildlife rehabilitation centers, Florida, United States, 2021-2024.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Oropouche virus (OROV) is an emerging vector-borne pathogen in the American tropics that is a significant cause of human disease. Over 100 traveler imported cases of OROV were recorded in the continental USA in 2024 (103 in Florida), elevating the risk of local transmission of OROV should competent insect vectors feed upon viremic humans. The only confirmed natural vector of OROV is Culicoides paraensis (Goeldi), a biting midge species that occurs throughout forested areas of the New World, including the eastern USA, Central America and most of northern South America. Anthropophagic mosquito species, especially Culex quinquefasciatus Say and Aedes aegypti L. have been suspected of transmitting emerging lineages of OROV in areas where C. paraensis had not been reported (Cuba). Recent laboratory studies have shown that emerging strains of OROV replicate to higher titers in human cell lines than ancestral strains, raising the possibility that these strains may also be transmitted by select mosquito species that feed on humans. To assess the potential for anthropophagic mosquitoes in the southern USA to transmit OROV, we evaluated the vector competence (based on viral RNA detection) of lab-adapted Cx. quinquefasciatus and Ae. aegypti, along with an F1 generation of Ae. aegypti from field-collected mosquitoes in Florida, using prototype (TRVL9760, Trinidad 1955) and emerging (240023, Cuba 2024) OROV genotypes across two incubation periods in cell culture (5 and 7 days) and three extrinsic (7, 14, and 21 days) incubation periods. Both mosquito species exhibited moderate susceptibility to infection (24.2-43.2%) and disseminated infection (23.0-57.5%), but low competence to transmit OROV. Transmission was observed in Ae. aegypti (2.5% in the Lower Keys strain and 1.8% in the Orlando strain) and Cx. quinquefasciatus (0.7%). When the two viral genotypes (TRVL9760 vs 240023) were compared at the same incubation conditions (IP/EIP), the emergent genotype did not exceed the prototype in infection, dissemination, or transmission. Our data indicates that these two relatively anthropophagic mosquito species are unlikely to serve as competent vectors of OROV in Florida, attributable to substantial midgut and salivary gland barriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.